Novartis Transderm Scop comparative claim removed
Executive Summary
Novartis relabels its Rx motion sickness product Transderm Scop (transdermal scopolamine) to remove language that the drug "provided significantly greater protection than that obtained with oral dimenhydrinate." Pharmacia, which markets OTC dimenhydrinate as Dramamine, petitioned for the removal (1"The Pink Sheet" April 16, 2001, p. 28). "FDA evaluated this statement and determined that it is not supported by any data" in the Transderm Scop NDA and asked Novartis to remove the language, agency says...
You may also be interested in...
Novartis Transderm Scop Superiority Claim Disputed By Pharmacia In Petition
Pharmacia is requesting that FDA modify the physician package insert for Novartis' Transderm Scop motion sickness patch to remove a statement claiming superiority to OTC oral dimenhydrinate.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.